Clene Inc.
NASDAQ:CLNN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Clene Inc.
NASDAQ:CLNN
|
US |
|
Y
|
YM Tech Co Ltd
KOSDAQ:273640
|
KR |
|
G
|
Greenpanel Industries Ltd
NSE:GREENPANEL
|
IN |
|
Chow Tai Fook Jewellery Group Ltd
OTC:CJEWY
|
HK |
|
Concurrent Technologies PLC
LSE:CNC
|
UK |
|
K
|
KAISA JiaYun Technology Inc
SZSE:300242
|
CN |
|
A
|
Arise AB
STO:ARISE
|
SE |
|
S
|
South Malaysia Industries Bhd
KLSE:SMI
|
MY |
|
T
|
Tempo Scan Pacific Tbk PT
IDX:TSPC
|
ID |
|
Shricon Industries Ltd
BSE:508961
|
IN |
|
Yalla Group Ltd
NYSE:YALA
|
AE |
|
P
|
Ponsse Oyj
OMXH:PON1V
|
FI |
|
A
|
Activision Blizzard Inc
LSE:0H8X
|
US |
|
Shanghai Guao Electronic Technology Co Ltd
SZSE:300551
|
CN |
|
V
|
Victorian Plumbing Group PLC
LSE:VIC
|
UK |
|
Better Life Commercial Chain Share Co Ltd
SZSE:002251
|
CN |
|
B
|
Boditech Med Inc
KOSDAQ:206640
|
KR |
|
IMAX China Holding Inc
HKEX:1970
|
CN |
Clene Inc.
Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutics for neurodegenerative diseases. The company is headquartered in Salt Lake City, Utah and currently employs 95 full-time employees. The company went IPO on 2018-08-27. The firm is focused on the treatment of neurodegenerative disease with potential first-in-class nanotherapeutics to treat energetic failure and neurological diseases. The Company’s lead drug candidate, CNM-Au8, is an oral suspension of gold nanocrystals that drive critical cellular energetic metabolism in the central nervous system (CNS). CNM-Au8 increases energy production and utilization to accelerate neurorepair and improve neuroprotection. CNM-Au8 is being evaluated in a Phase III registration trial in amyotrophic lateral sclerosis (ALS) and a Phase II trial for the treatment of chronic optic neuropathy in patients with stable relapsing multiple sclerosis (MS). The firm has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses.
Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutics for neurodegenerative diseases. The company is headquartered in Salt Lake City, Utah and currently employs 95 full-time employees. The company went IPO on 2018-08-27. The firm is focused on the treatment of neurodegenerative disease with potential first-in-class nanotherapeutics to treat energetic failure and neurological diseases. The Company’s lead drug candidate, CNM-Au8, is an oral suspension of gold nanocrystals that drive critical cellular energetic metabolism in the central nervous system (CNS). CNM-Au8 increases energy production and utilization to accelerate neurorepair and improve neuroprotection. CNM-Au8 is being evaluated in a Phase III registration trial in amyotrophic lateral sclerosis (ALS) and a Phase II trial for the treatment of chronic optic neuropathy in patients with stable relapsing multiple sclerosis (MS). The firm has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses.
